Pharmacological interventions for obsessive-compulsive personality disorder

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 3, 2014, Pages

  Alex, Rajesh ^a   Ferriter, Michael ^a   Jones, Hannah F ^b   Huband, Nick ^b   Duggan, Conor ^b   Völlm, Birgit A ^b   Stoffers, Jutta M ^c,d   Lieb, Klaus ^d  

^a RAMPTON HOSPITAL   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c UNIVERSITY OF FREIBURG   (Germany)

^d UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; PRIORITY JOURNAL; RETRACTED ARTICLE;

EID: 85041823445     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD008517.pub2     Document Type: Article

References (46)

1. Altman DG, Bland JM. Detecting skewedness from summary information. BMJ 1996;313:1200.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders - Text Revision (DSM-IV-TR). Washington DC: American Psychiatric Association, 2000.
3. Attkisson CC, Zwick R. The client satisfaction questionnaire. Psychometric properties and correlations with service utilization and psychotherapy outcome. Evaluation and Program Planning 1982;5:233-7.
4. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Archives of General Psychiatry 1961;4:561-71.
5. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. Journal of Consulting and Clinical Psychology 1988;56:893-7.
6. Joint Formulary Committee. British National Formulary. London: BMJ Publishing Group Ltd, March 2009.
7. Clomipramine Collaborative Study Group. Clomipramine in the treatment of patients with obsessive-compulsive disorder. Archives of General Psychiatry 1991;48:730-8.
8. Coccaro EF, Kavoussi RJ, Hauger RL, Cooper TB, Ferris CF. Cerebrospinal fluid vasopressin levels: correlates with aggression and serotonin function in personality-disordered subjects. Archives of General Psychiatry 1998;55:708-14.
9. Cowdry RW, Gardner DL. Pharmacotherapy of borderline personality disorder: alprazolam, carbamazepine, trifluoperazine and tranylcypromin. Archives of General Psychiatry 1989;45:111-9.
10. Donner A, Piaggio G, Villar J. Statistical methods for the meta-analysis of cluster randomization trials. Statistical Methods in Medical Research 2001;10(5):325-38.
11. Egger M, Davey-Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
12. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
13. EuroQoL Group. EuroQoL: a new facility for measurement of health-related quality of life. Health Policy 1990;16:199-208.
14. Follmann D, Elliot P, Suh I, Cutler J. Variance imputation for overviews of clinical trials with continuous response. Journal of Clinical Epidemiology 1992;45(7):769-73.
15. Gamble C, Hollis S. Uncertainty method on best-worst case analysis in a binary meta-analysis. Journal of Clinical Epidemiology 2005;58(6):579-88.
16. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, et al.The Yale-Brown obsessive compulsive scale 1: development, use and reliability. Archives of General Psychiatry 1989;46:1006-11.
17. Greve KW, Adams D. Treatment of features of obsessive-compulsive personality disorder using carbamazepine. Psychiatry and Clinical Neurosciences 2002;56:207-8.
18. Grilo CM. Factor structure of DSM-IV criteria for obsessive compulsive personality disorder in patients with binge eating disorder. Acta Psychiatrica Scandinavica 2004;109:64-8.
19. Hamilton M. The assessment of anxiety states by rating. British Journal of Medical Psychology 1959;32:50-5.
20. Hamilton M. Standardised assessment and recording od depressive symptoms. Psychiatria, Neuralgia, Neurochirurgia 1969;72(2):201-5.
21. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org.
22. Hodgson RJ, Rachman S. Obsessive-compulsive complaints. Behaviour Research and Therapy 1977;15:389-95.
23. Links P. Lithium therapy for borderline patients. Journal of Personality Disorders 1990;4:173-81.
24. Markovitz PJ. Recent trends in the pharmacotherapy of personality disorders. Journal of Personality Disorders 2004;18(1):90-101.
25. Nestadt G, Romanoski AJ, Brown CH, Chahal R, Merchant A, Folstein MF, et al.DSM-III compulsive personality disorder: an epidemiological survey. Psychological Medicine 1991;21:461-71.
26. Newton-Howes G, Tyrer P, Johnson T. Personality disorder and the outcome of depression: meta-analysis of published studies. British Journal of Psychiatry 2006;188:13-20.
27. Nigg JT, Goldsmith HH. Genetics of personality disorders: perspectives from personality and psychopathology research. Psychological Bulletin 1994;115:346-80.
28. Pfohl B, Blum N. Obsessive compulsive personality disorder, the DSM IV personality disorder. New York: Guilford Press, 1995.
29. Pollak JM. Relationship of obsessive-compulsive personality to obsessive-compulsive disorder: a review of the literature. Journal of Psychology 1987;121:137-48.
30. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
31. Samuels J, Eaton WW, Bienvenu OJ, Brown CH, Costa PT, Nestadat G. Prevalence and correlates of personality disorders in a community sample. British Journal of Psychiatry 2002;180:536-42.
32. Serpell L, Livingstone A, Neiderman M, Lask B. Anorexia nervosa: obsessive-compulsive disorder, obsessive-compulsive personality disorder, or neither?. Clinical Psychology Review 2002;22:647-69.
33. Skodol AE, Siever LJ, Livesley WJ, Gunderson JG, Pfohl B, Widiger TA. The borderline diagnosis II: biology, genetics and clinical course. Biological Psychiatry 2002;51:951-63.
34. Soloff PH. Algorithms for pharmacological treatment of personality dimensions. Symptom-specific treatments for cognitive-perceptual, affective, and impulsive-behavioral dysregulation. Bulletin of the Menninger Clinic 1998;62:195-214.
35. Spielberg CD, Gorsuch RL, Luchene R, Vagg PR, Jacobs GA. Manual for the State-Trait Anxiety Inventory. Palo Alto, CA: Consulting Psychologists Press, 1983.
36. Stein GS. Drug treatment of the personality disorders. British Journal of Psychiatry 1992;161:167-84.
37. Stein DJ, Hollander E. The spectrum of obsessive compulsive related disorders. Obsessive-compulsive related disorders. Vol. 1, Washington DC: American Psychiatric Press, 1993:241-62.
38. Stein DJ, Simeon D, Frenkel M, Islan MN, Hollander E. An open trial of valproate in borderline personality disorder. Journal of Clinical Psychiatry 1995;56:506-10.
39. Tyrer P, Bateman AW. Drug treatment for personality disorders. Advances in Psychiatric Treatment 2004;10:389-98.
40. Tyrer P, Nur U, Crawford M. The Social Functioning Questionnaire: a rapid and robust measure of perceived functioning. International Journal of Social Psychiatry 2005;51:265-75.
41. Ware JE, Snow KK, Kosinski M, Gandek B. Health Survey Manual and Interpretation Guide. SF-36 Health Survey Manual and Interpretation Guide. Boston: New England Medical Centre, 1993.
42. Warren F, Preedy-Fayers K, McGauley G, Pickering A, Norton K, Geddes JR, et al.Review of treatments for severe personality disorder. London: Home Office, 2001.
43. Weissman MM, Bothwell S. Assessment of social adjustment by patient self-report. Archives of General Psychiatry 1976;33:1111-15.
44. World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders. 10th Edition. Geneva: WHO, 1992.
45. Wilcox JA. Divalproex sodium as a treatment for borderline personality disorder. Annals of Clinical Psychiatry 1995;7(1):33-7.
46. Zimmerman M, Rothschild L, Chelminski I. The prevalence of DSM-IV personality disorders in psychiatric outpatients. American Journal of Psychiatry 2005;162:1911-18.